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Summary: In this study four commercially available cAMP kits were compared and shown to differ with respect to
reliability, sensitivity, simplicity and expiration time.
It is not possible to recommend a particular kit, because the choice depends on the demands of the investigator,
which, of course, may vary. However, in our opinion, one of the kits was inferior to the others.
Vergleich von vier kommerziell erhältlichen cAMP-Kits
Zusammenfassung: In dieser Studie werden vier kommerziell verfügbare cAMP-Kits verglichen. Zuverlässigkeit,
Sensitivität, Simplizität und Haltbarkeit wurden untersucht und Unterschiede festgestellt.
Es ist nicht möglich, einen speziellen Kit zu empfehlen, weil die Wahl abhängig ist von den Anforderungen des Unter-
suchers, die selbstverständlich verschieden sind. Unserer Meinung nach jedoch war einer der Kits minderwertig.
Introduction
Since Sutherland & Rail discovered cAMP in 1958 (1),
many investigations have been carried out on the bio-
logical role of this substance (2).
For the determination of cAMP a competitive protein
binding assay has been developed by Gilman (3) and a
rädiöimmunoassay by Steiner et al (4). Both techniques
have been commercially adapted.
The results of the comparison of four commercially
kits are reported. Of these kits three were competitive
protein binding assays and one a rädiöimmunoassay.
These kits have been compared with respect to reliability,
sensitivity, simplicity and expiration time.
Materials and Methods
Reagents
The following kits were used: Amersham (The Radio chemical
Centre, Amersham, Buckinghamshire, U.K.), Diagnostic Products
(Diagnostic Products Corporation, Los Angeles, Ca., U.S.A.),
Boehiinger (Boehringer, Mannheim GmbH, Germany) and
Schwarz-Mann (Becton, Dickinson and Company,.New York,
. ., . . .)1).
*) In the text the following abbreviations are used: Amersham =
A, Diagnostic Products = B, Boehringer = C, Schwarz-Mann = D.
The following chemicals were used: trichloioacetic acid p.a.,
tris-(hydroxymethyl)-aminomethane p.a. and magnesium
chloride (MgCl2.6H2O) p.a. from Merck (Darmstadt, Germany),
diethyl ether and hydrochloric acid (HC1) from British Drug
Houses (Poole, U.K.), 0-mercaptoethanolp.a. and Dowex 1 X 2
100/200 mesh from Fluka (Buchs, Switzerland). Phosphodiesterase
(from beef heart in 500 g/1 glycerol) was obtained from Boehrin-
ger (Mannheim GmbH, Germany), Instagel (scintillation liquid
for aqueous and non-aqueous samples) from Packard (Downer's
Grove, DL, U.S.A.), Ficoll-Paque from Pharmacia Fine Chemicals
(Uppsala, Sweden) and isoproterenol from Sigma (St. Louis, Mo.,
U.S.AO-
[8-3H]adenosine 3',5'-cyclic phosphate, ammonium salt (batch
22, specific activity/1.0 PBq/mol) was obtained from the Radio-
chemical Centre (Amersham, Buckinghamshire, U.K.). Before
use its purity was checked by paper chromatography (5).
Procedure
Preparation of extracts
Lymphocytes were isolated according to a slightly modified
procedure ofBtfyum (6) on a ficoll gradient (purity of lympho-
cytes obtained 95%). Stimulation of the cAMP content of the
lymphocytes was carried out as described by Gillespie et al (7).
the extracts LO, L5, L4, L4', L3 were stimulated with 0,10,
100,1000 / isoproterenol respectively.
Mammary cancer tissue was obtained during surgery. After
freezing in liquid nitrogen the tissue was homogenized with a
microdismembrator (B. Braun, M eisungen).
Urine was diluted 1:100 with demineralized water.
Extraction ofcAMP from the lymphocytes and mammary
cancer tissue was performed as described by Gilman (8). The
diluted urine was used directly in the assay.
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To correct for losses during extraction and purification (3HJ
cAMP was added as an internal standard.
Purification of the extracts
The extracts were purified over a Dowex 1 X 2 column as
described by Mao &, Guidotti (9). By this procedure cAMP is
separated from cGMP.
Phosphodiesterase test
The phosphodiesterase test was performed with some minor
modifications as described in the protocol of kit C.
Determination ofcAMP
The experimental setting of the assays of the different kits is
scheduled in table 1 (method of determination, incubation,
separation, counting system and comments). Computation of
the cAMP values was performed according to the instructions
enclosed by the manufacturers.
Results
First the purification procedure by Dowex 1 X 2
column chromatography was examined. The radioactive
elution pattern obtained by applying a mixture of
[14C]cAMP and [3H]-cGMP was identical to that reported
by Mao (9).
In seven different extracts the cAMP contents were
measured with the four cAMP kits before and after
purification. The results of these measurements are
shown in figure 1.
From this figure it can be seen that the kits C and D tend
to give higher values after the purification procedure.
In addition the values measured with these two kits are
somewhat higher than those obtained with kit A and B.
Furthermore kit B seems relatively insensitive for sub-
stances eliminated by the purification procedure.
In figure 2 the results are presented of the recovery of
pure cAMP added to the extracts. For these studies the
standard preparations provided with the kits were used
The results of the addition experiments, carried out in
both unpurified and purified extracts, are expressed as
AcAMP measured/AcAMP added* which ideally should
be unity (figure 2). Furthermore two-fold concentration
experiments were performed (once again before and
after purification). The results of these tests are presented
as the ratio of the cAMP content of the double versus the
single concentration (fig. 3).
From figure 2 it is evident, that the values measured
tend to scatter less after purification. With all kits tested
the points after purification concentrate around 1.00.
Moreover the deviation in the measurements is decreased
after purification. In unpurified extracts, kit C, and to a
lesser extent kit D, give an underestimation of the
amount of pure eAMP added. This is in accordance with
figure 1 in which kit C and kit D show a considerable
rise in measured cAMP concentrations after purification.
In our opinion the data of the two-fold concentration ex-
periments give less information; it is remarkable that
even after purification kit C gives ratios which remain
smaller than 2.00. This may be caused by the fact that
in the low concentration range kit C overestimates the
cAMP contents.
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Fig. 1. The cAMP contents of the seven extracts measured with the four kits before and after purification. All values were
measured four times (the mean value and the range are shown). They have been corrected for losses during the extraction
and purification procedures by means of the internal standard. The values for the lymphocyte extracts (LO, L5, L4, L4','L3)
are expressed as pmpl/106 lymphocytes; L4 and L4' are extracts from different samples. The cAMP content of the mammary
tumour extract (M) is expressed as μηιοΐ/kg tissue and that of the urine (U) as μπιρί/ΐ.
b = before purification, a = after purification.
Kit A B C ...... D -.-—.-.
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Fig. 2. Results of the addition experiments expressed as Δ standard cAMP measured/Astandard cAMP added (the mean value and the
range are shown). The meaning of the symbols is the same as in figure 1.
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Fig. 3. Results of the double amount experiments expressed as the ratio of the double versus the single cAMP concentration (the
mean value and the range are shown). The meaning of the symbols is the same as in figure 1.
To verify the identity of the substance measured with
the different kits, a phosphodiesterase test was per-
formed in extracts L5, L4, L3 and M. The test was
applied to both unpurified and purified extracts. After
phosphodiesterase treatment of the extracts, none of
the kits detected a significant amount of cAMP, with
the exception of extract M before purification (the
average amount cAMP not hydrolysed in this extract
was 75% of the initial value).
Intra-assay variations for the four kits were 4.1% for
kit A, 5.5% for B, 7.4% for C and 14.5% for D. No
attempt was made to determine the interassay variation.
Discussion
The cAMP values found in the lymphocytes and in the
urine are in accordance with those in the literature (7,8,
10,11,12). The cAMP content in the mammary cancer
tissue extract is about twenty-fold lower than found by
Minton et al (13) and about four times lower than
reported by Guerinot & Bohuon (14), presumably because
the tissue was not immediately frozen in liquid nitrogen
after surgical removal of the tumour.
The incomplete hydrolysis of cAMP in the unpurified
extract M was probably caused by an inhibitor of the
phosphodiesterase, which was removed by purification.
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This explanation is based on the observation that the
cAMP contents measured in this extract before and
after purification showed no significant differences.
The results shown above demonstrate that the analytical
properties of the four kits are different. In our opinion,
the order of the reliability of the different kits is: A =
B > D > C. Apart from this, other factors are important
for the final appreciation of the different kits, which
are listed in table 1 under comments.
A remarkable difference between the kits is the range
over which cAMP can be measured. Important factors
that determine the characteristics of an assay system are
the specific activity of the label, the amount of label
added, the amount of binding protein or anti-serum added,
the dissociation constants of these proteins and the final
volume of the incubation mixture (15, 16). Because we
did not measure the kinetic properties of the binding
proteins and the anti-serum, a complete analysis of the
characteristics of the kits in terms of the choice of the
amount and quality of the reagents used is not possible.
The assay system of kit A and the (freedom from) inter-
ference by non-specific materials has been fully described
by roveyetal(17).
During the time this paper was in preparation kit C was
modified in two ways. Firstly, instead of the filtration
step, an ammonium sulphate precipitation was intro-
duced to separate bound from free cAMP, which simpli-
fies the performance of the assay. Secondly, to stabilize
the binding protein an immuno globulin (IgG) was added.
The high sensitivity (0.1-2 pmol/tube) claimed by the
manufacturer for the unmodified kit could only be
reached if the kit was used directly within a month,
long before the stated expiration time (personal
communication). Thereafter the slope of the standard
curve gradually diminished. The stabilisation of the
binding protein might have improved the kit in this
respect.
Furthermore, a modification in the radioimmunoassay
of cAMP originally developed by Harper & Brooker (18)
was recently introduced commercially (New England
Nuclear). This makes it possible to measure even smaller
amounts of cAMP (0.0025-0.50 pmol/tube); before
being assayed the cAMP (from extract and standard
preparation) is first acetylated.
In conclusion we would like to emphasize that it is not
possible to recommend a particular kit, because the
choice to be made depends on the demands of the
investigator, which, of course, may vary. However, in
our opinion the unmodified kit C was inferior to the
others. On the basis of our investigation we have decided
to use kit B.
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